Revelation Biosciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 1.45 million compared to USD 1.83 million a year ago. Basic loss per share from continuing operations was USD 7.5 compared to USD 124.8 a year ago. Diluted loss per share from continuing operations was USD 7.5 compared to USD 124.8 a year ago.
For the six months, net income was USD 4.71 million compared to net loss of USD 8.45 million a year ago. Basic earnings per share from continuing operations was USD 48.3 compared to basic loss per share from continuing operations of USD 591.3001 a year ago. Diluted earnings per share from continuing operations was USD 45.9 compared to diluted loss per share from continuing operations of USD 591.3001 a year ago.